trial

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

NCTId NCT00567203
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 36 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2008-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2007-11
Primary completion
2008-05
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-3463275

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

2 total
Glendale, United StatesWillingboro, United States

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE1
Primary Completion Date
2008-05
Status
COMPLETED
relationships
The graph out of here
drug
PF-3463275
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication